niacinamide has been researched along with Extravascular Hemolysis in 19 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib (SF) is a U." | 5.42 | Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma. ( Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS, 2015) |
| "Sorafenib (Nexavar(®)), a polytyrosine kinase inhibitor, stimulates apoptosis and is thus widely used for chemotherapy in hepatocellular carcinoma (HCC)." | 3.78 | Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study. ( Bitzer, M; Föller, M; Jilani, K; Lang, E; Lang, F; Lupescu, A; Pasham, V; Plate, A; Qadri, SM; Shaik, N; Zbidah, M; Zelenak, C, 2012) |
| "We previously reported a flow cytometry technique to monitor pharmacodynamic effects of the raf kinase inhibitor BAY 43-9006 based on the ability of phorbol ester (PMA) to phosphorylate extracellular-regulated kinase (ERK) in peripheral blood (Chow et al." | 2.72 | Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. ( Chow, S; Hedley, D; Tong, FK, 2006) |
| "Sorafenib-LNS were prepared by nanoprecipitation and consisted of spherical particles with a uniform size distribution (164." | 1.43 | In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. ( Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N, 2016) |
| "Sorafenib (SF) is a U." | 1.42 | Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma. ( Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, R | 1 |
| Nigam, L | 1 |
| Singh, AP | 1 |
| Singh, K | 1 |
| Subbarao, N | 1 |
| Dey, S | 1 |
| Khan, MA | 1 |
| Ali, S | 1 |
| Venkatraman, SS | 1 |
| Sohail, MF | 1 |
| Ovais, M | 1 |
| Raza, A | 1 |
| Dang, T | 1 |
| Nizamov, IS | 1 |
| Salikhov, RZ | 1 |
| Sabirzyanova, LR | 1 |
| Vorobev, VV | 1 |
| Burganova, TI | 1 |
| Shaidoullina, MM | 1 |
| Batyeva, ES | 1 |
| Cherkasov, RA | 1 |
| Abdullin, TI | 1 |
| Al Balushi, H | 1 |
| Dufu, K | 1 |
| Rees, DC | 1 |
| Brewin, JN | 1 |
| Hannemann, A | 1 |
| Oksenberg, D | 1 |
| Lu, DC | 1 |
| Gibson, JS | 1 |
| van der Aa, LJ | 1 |
| Vader, P | 1 |
| Storm, G | 1 |
| Schiffelers, RM | 1 |
| Engbersen, JF | 1 |
| Bondì, ML | 2 |
| Botto, C | 2 |
| Amore, E | 2 |
| Emma, MR | 1 |
| Augello, G | 1 |
| Craparo, EF | 1 |
| Cervello, M | 2 |
| Thapa, RK | 2 |
| Choi, JY | 2 |
| Poudel, BK | 2 |
| Hiep, TT | 1 |
| Pathak, S | 1 |
| Gupta, B | 1 |
| Choi, HG | 2 |
| Yong, CS | 2 |
| Kim, JO | 2 |
| Scala, A | 1 |
| Sortino, G | 1 |
| Azzolina, A | 1 |
| Balasus, D | 1 |
| Mazzaglia, A | 1 |
| Terracciano, M | 1 |
| Shahbazi, MA | 1 |
| Correia, A | 1 |
| Rea, I | 1 |
| Lamberti, A | 1 |
| De Stefano, L | 1 |
| Santos, HA | 1 |
| Yang, S | 1 |
| Zhang, B | 1 |
| Gong, X | 1 |
| Wang, T | 1 |
| Liu, Y | 2 |
| Zhang, N | 1 |
| Yang, J | 1 |
| Wang, X | 1 |
| Liu, J | 1 |
| Wang, Z | 1 |
| Liu, H | 1 |
| Chen, L | 1 |
| Berchem, G | 1 |
| Dewilde, S | 1 |
| Mahassen, P | 1 |
| Zhang, JY | 1 |
| He, B | 1 |
| Qu, W | 1 |
| Cui, Z | 1 |
| Wang, YB | 1 |
| Zhang, H | 1 |
| Wang, JC | 1 |
| Zhang, Q | 1 |
| Lupescu, A | 1 |
| Shaik, N | 1 |
| Jilani, K | 1 |
| Zelenak, C | 1 |
| Lang, E | 1 |
| Pasham, V | 1 |
| Zbidah, M | 1 |
| Plate, A | 1 |
| Bitzer, M | 1 |
| Föller, M | 1 |
| Qadri, SM | 1 |
| Lang, F | 1 |
| Tong, FK | 1 |
| Chow, S | 1 |
| Hedley, D | 1 |
| Markova, NA | 1 |
| Agranenko, VA | 1 |
| Tibilova, NN | 1 |
| Volkova, RI | 1 |
| Graff, KS | 1 |
| Mengel, CE | 1 |
| Balcerzak, SP | 1 |
| Lin, LF | 1 |
| Lan, SJ | 1 |
| Richardson, AH | 1 |
| Henderson, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy[NCT01869114] | Phase 2 | 57 participants (Actual) | Interventional | 2013-07-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Extravascular Hemolysis
18 other studies available for niacinamide and Extravascular Hemolysis
| Article | Year |
|---|---|
Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in cellular model of Alzheimer's disease.
Topics: Allosteric Regulation; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cell Line, Tum | 2017 |
Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Butadienes; Cell Survival; Drug Carriers; Drug | 2018 |
Synthesis and characterization of pyridoxine, nicotine and nicotinamide salts of dithiophosphoric acids as antibacterial agents against resistant wound infection.
Topics: Anti-Bacterial Agents; Fibroblasts; Gram-Negative Bacteria; Hemolysis; Humans; Methicillin-Resistant | 2019 |
The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Cell Size; Erythrocyte Membrane; Hemoglobin | 2019 |
Intercalating quaternary nicotinamide-based poly(amido amine)s for gene delivery.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; DNA; Erythrocytes; Gene E | 2014 |
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Topics: Antineoplastic Agents; Caprylates; Cell Survival; Chromatography, High Pressure Liquid; Delayed-Acti | 2015 |
Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Calorimetry, Differential Scanning; Carcinoma, Hepatocellular; Cell Survival; Dr | 2015 |
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
Topics: Adamantane; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Survival; Cyclodextr | 2015 |
Surface bioengineering of diatomite based nanovectors for efficient intracellular uptake and drug delivery.
Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Cell-Penetrating Pe | 2015 |
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hep | 2016 |
Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Death; Drug Carriers; Endocytosis; Folat | 2016 |
In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate.
Topics: Acrylic Resins; alpha-Tocopherol; Animals; Cell Line, Tumor; Chemistry Techniques, Synthetic; Cystam | 2016 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobin | 2009 |
Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cattle; Cell Line, Tumor; Drug Carriers; Female; | 2011 |
Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Size; Cer | 2012 |
Combined action of nicotinamide and adenine in preservation of packed red cells.
Topics: Adenine; Blood Preservation; Blood Transfusion; Erythrocyte Aging; Erythrocyte Transfusion; Hemolysi | 1987 |
Inhibition of in vitro PNH erythrocyte lysis by tryptophan metabolites.
Topics: Anemia, Hemolytic; Culture Techniques; Erythrocytes; Glutathione; Hemoglobinuria, Paroxysmal; Hemoly | 1969 |
Pyridine nucleotide synthesis. Purification of nicotinamide mononucleotide pyrophosphorylase from rat erythrocytes.
Topics: Adenosine Triphosphate; Ammonium Sulfate; Animals; Carbon Isotopes; Chromatography, DEAE-Cellulose; | 1972 |